"We also have to remember that the world is changing when it comes to medicine pricing. Australia has negotiated very good deals for a long time but we are coming under increasing scrutiny," said AbbVie's Chris Stemple.
AbbVie's Chris Stemple: Australia facing increased scrutiny on pricing
January 11, 2021 Latest NewsBioPharmaDispatch Executive
Latest Video
New Stories
-
Pharmac announces plan to update access and supply of COVID-19 treatments
August 12, 2025 - - Latest News -
If the cost of this process is truly rising at this rate, then the process must be the problem
August 12, 2025 - - Latest News -
Biogen announces leadership transition for Australia and New Zealand
August 12, 2025 - - Latest News -
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech -
Noxopharm advances HERACLES trial for novel autoimmune disease drug
August 11, 2025 - - Australian Biotech -
Could the realities of AI quickly date or even swamp the HTA Review outcomes?
August 11, 2025 - - Latest News -
We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review
August 10, 2025 - - Latest News